多发性骨髓瘤新进展：第57届美国血液学会年会报道

Recent progress of multiple myeloma： reports from the 57th American Society of Hematology annual meeting

第57届美国血液学会（ASH）年会在多发性骨髓瘤的诊治方面取得了令人瞩目的进展。年会上报道了最新的蛋白酶体抑制剂（PI）、免疫抗体（antibody）、检测点阻滞剂（checkpointblockade）、免疫调节剂（IMiD）、组蛋白去乙酰化酶抑制剂（HDACI）等药物和嵌合抗原受体T细胞（CAR—T）治疗方法的疗效及新的诊断技术。这些促成了该届ASH年会的一个重要议题就是优化诊断治疗。目前不论使用何种新药，各个临床试验都强调了联合用药的重要性，再加上造血干细胞移植治疗，可以将疗效进一步提高。因此有研究者也将2015年称为“多发性骨髓瘤治疗进展年”。

The diagnosis and treatment of multiple myeloma （MM） have make remarkable progress, which were reviewed in the 57th American Society of Hematology （ASH） annual meeting. In this annual meeting, the effects of advanced proteasome inhibitor （PI）, antibody, checkpoint blockade, immunomodulatory agent （IMiD）, histone deacetylase （HDACI） and chimeric antigen receptor T-cell （CAR-T）, and new diagnostic technologies were reported. The real point is to apply the best available diagnosis and therapy at this meeting. At present, regardless of advances, all of randomized clinical trials push to combined agents, and combined with hematopoietic stem cell transplantation, efficacy will be improved in further. So some professors also refered to 2015 year as ＇the advance year of MM＇.